Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250
May 16, 2018 8:31 AM EDTAlbireo Pharma, Inc. (NASDAQ: ALBO) today announced the first patient has been enrolled in PEDFIC-1, a Phase 3 clinical trial of lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).
A PFIC diagnosis for our children was shocking and devastating, and we quickly found out that current treatment options are inadequate, said Kristen and Michael Busby of New York, parents of two children with PFIC. We applaud all research in this area, and it is great news... More
